Facebook-f Twitter Linkedin Youtube
SUBSCRIBE
Facebook-f Twitter Linkedin Youtube

Identifying a Clear Path Through the Changing Maze of AML Management

Program Overview

Acute myeloid leukemia (AML), the most common form of leukemia, is characterized by a wide range of cytogenetic and molecular aberrations. These aberrations determine risk classification and, if available, targeted therapy. Recent data has changed the diagnostic threshold for AML, as well as risk classification and data on emerging therapies, by reshaping the future of treatment for newly diagnosed and relapsed/refractory AML. Join Drs. Amer Zeidan and Kendra Sweet as they discuss these and other recent updates in AML.

Credit Expired

Target Audience

Hematology, medical oncology, and radiation oncology clinicians managing patients with acute myeloid leukemia (AML)  

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Implement molecular testing at diagnosis and relapse to help guide treatment selection in patients with acute myeloid leukemia (AML)
  • Integrate available data on novel therapies into the treatment paradigm of newly diagnosed AML
  • Utilize current evidence on novel therapies when treating patients with relapsed/refractory AML
  • Manage the unique adverse events associated with the use of novel therapeutics for AML

Activity Faculty

Amer Zeidan, MBBS, MHS

Amer Zeidan, MBBS, MHS

Associate Professor, Medicine (Hematology)
Yale Cancer Center
Yale University
New Haven, CT

Kendra Sweet, MD, MS

Kendra Sweet, MD, MS

Associate Member, Malignant Hematology Faculty
Medical Director, Clinical Research
Department of Malignant Hematology
H. Lee Moffitt Cancer Center
Tampa, FL

Resources

Featured RMEI CE Activities – Earn CE Credit(s)

VIEW All RMEI CE ACTIVIES

Copyright © 2024. RMEI Medical Education, LLC. All rights reserved​

Privacy | Terms of Use

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources

Join Now!